RedHill Biopharma | RDHL

Stock Price
1.43
Daily Change
0.20 16.54%
Monthly
16.54%
Yearly
-84.72%
Q3 Forecast
1.42

Peers Price Chg Day Year Date
Clal Biotechnology 32.00 0.40 1.27% -17.53% Sep/04
Compugen 479.60 -2.50 -0.52% -33.09% Sep/04
Cronos Group 3.48 0.03 0.87% 20.42% Sep/05
RedHill Biopharma 1.43 0.20 16.54% -84.72% Sep/05

Indexes Price Day Year Date
USND 21700 -7.31 -0.03% 30.01% Sep/05

RedHill Biopharma traded at $1.43 this Friday September 5th, increasing $0.20 or 16.54 percent since the previous trading session. Looking back, over the last four weeks, RedHill Biopharma gained 16.54 percent. Over the last 12 months, its price fell by 84.72 percent. Looking ahead, we forecast RedHill Biopharma to be priced at 1.42 by the end of this quarter and at 1.39 in one year, according to Trading Economics global macro models projections and analysts expectations.

Redhill Biopharma Ltd is an Israel-basedis a specialty biopharmaceutical company, primarily focused on gastrointestinal and infectious diseases. The Company promotes three gastrointestinal drugs in the US: Movantik, Talicia and Aemcolo. Key programs in it pipeline of late-stage clinical assets include: opaganib (Yeliva) and RHB-107 for multiple indications including COVID-19, RHB-204 for pulmonary nontuberculous mycobacteria (NTM) disease and RHB-104 for Crohn's disease.